Find UNII-UF6PC17XAV manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1650550-25-6, Ag-221 mesylate, Enasidenib mesilate, Enasidenib methanesulfonate, Enasidenib (mesylate), Uf6pc17xav
Molecular Formula
C20H21F6N7O4S
Molecular Weight
569.5  g/mol
InChI Key
ORZHZQZYWXEDDL-UHFFFAOYSA-N
FDA UNII
UF6PC17XAV

UNII-UF6PC17XAV
Enasidenib Mesylate is the mesylate salt form of enasidenib, an orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits various mutant forms of IDH2, including the IDH2 variants R140Q, R172S, and R172K, which inhibits the formation of 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH2-expressing tumor cells. IDH2, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by blocking differentiation and the production of the oncometabolite 2HG.
1 2D Structure

UNII-UF6PC17XAV

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
methanesulfonic acid;2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol
2.1.2 InChI
InChI=1S/C19H17F6N7O.CH4O3S/c1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25;1-5(2,3)4/h3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32);1H3,(H,2,3,4)
2.1.3 InChI Key
ORZHZQZYWXEDDL-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC(C)(CNC1=NC(=NC(=N1)C2=NC(=CC=C2)C(F)(F)F)NC3=CC(=NC=C3)C(F)(F)F)O.CS(=O)(=O)O
2.2 Other Identifiers
2.2.1 UNII
UF6PC17XAV
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. 1650550-25-6

2. Ag-221 Mesylate

3. Enasidenib Mesilate

4. Enasidenib Methanesulfonate

5. Enasidenib (mesylate)

6. Uf6pc17xav

7. Enasidenib Mesylate [usan]

8. Cc-90007

9. 1650550-25-6 (mesylate)

10. Enasidenib Mesylate (usan)

11. 2-propanol, 2-methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-, Methanesulfonate (1:1)

12. 2-methyl-1-[4-(6-trifluoromethyl-pyridin-2-yl)-6-(2-trifluoromethyl-pyridin-4-ylamino)-[1,3,5]triazin-2-ylamino]-propan-2-ol Mesylate

13. Methanesulfonic Acid;2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol

14. Unii-uf6pc17xav

15. Idhifa (tn)

16. Chembl3989931

17. Enasidenib Mesylate [mi]

18. Schembl16448052

19. Dtxsid501027943

20. Bcp26166

21. Ex-a1972

22. Enasidenib Mesylate [who-dd]

23. Hy-18690a

24. S4929

25. Enasidenib Mesylate; Ag-221 Mesylate

26. At36098

27. Cs-7541

28. Enasidenib Mesylate [orange Book]

29. Ac-31319

30. D11044

31. Q27291054

32. 2-methyl-1-((4-(6-(trifluoromethyl)pyridin-2-yl)- 6-((2-(trifluoromethyl)pyridin-4-yl)amino)-1,3,5-triazin- 2-yl)amino)propan-2-ol Methanesulfonate

2.4 Create Date
2015-02-23
3 Chemical and Physical Properties
Molecular Weight 569.5 g/mol
Molecular Formula C20H21F6N7O4S
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count17
Rotatable Bond Count6
Exact Mass569.12799232 g/mol
Monoisotopic Mass569.12799232 g/mol
Topological Polar Surface Area172 Ų
Heavy Atom Count38
Formal Charge0
Complexity727
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Pharmacology and Biochemistry
4.1 FDA Pharmacological Classification
4.1.1 Pharmacological Classes
Isocitrate Dehydrogenase 2 Inhibitors [MoA]; Isocitrate Dehydrogenase 2 Inhibitor [EPC]

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty